Literature DB >> 3814462

Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls.

F M Gengo, S C Fagan, G Krol, H Bernhard.   

Abstract

Six biopsy proven cirrhotics and five age-matched controls (mean 55.3 vs 52.4 years) were randomly given single 60 mg p.o. and 30 mg s.l. doses of nimodipine. Serum concentrations and blood pressure were measured regularly over the subsequent 24 h period. The clearance of nimodipine was reduced in the patients with cirrhosis. Apparent oral clearance of nimodipine in the cirrhotic group was significantly lower than that observed in the normal group (187 +/- 163 l h-1 vs 469.6 +/- 198.4 l h-1, P less than 0.01). There were no significant changes in mean arterial pressure (MAP) in the normal subjects. There were, however, significant reductions in MAP following oral nimodipine in the cirrhotics. These reductions were significantly related to nimodipine concentrations in individual patients (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814462      PMCID: PMC1386139          DOI: 10.1111/j.1365-2125.1987.tb03008.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  SHAM, a method for biexponential curve resolution using initial slope, height, area and moment of the experimental decay type curve.

Authors:  O Caprani; E Sveinsdottir; N Lassen
Journal:  J Theor Biol       Date:  1975-08       Impact factor: 2.691

2.  Effect of route of administration on the relationship between -adrenergic blockade and plasma propranolol level.

Authors:  C R Cleaveland; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

3.  Clearance concepts in pharmacokinetics.

Authors:  M Rowland; L Z Benet; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

4.  Relative potency and selectivity of calcium antagonists used in the treatment of migraine.

Authors:  S J Peroutka; S B Banghart; G S Allen
Journal:  Headache       Date:  1984-03       Impact factor: 5.887

5.  The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle.

Authors:  R Towart; E Wehinger; H Meyer; S Kazda
Journal:  Arzneimittelforschung       Date:  1982

6.  Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage.

Authors:  K D Rämsch; G Ahr; D Tettenborn; L M Auer
Journal:  Neurochirurgia (Stuttg)       Date:  1985-05

Review 7.  Propranolol disposition in chronic liver disease: a physiological approach.

Authors:  R A Branch; D G Shand
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and radiological findings.

Authors:  F Espinosa; B Weir; T Overton; W Castor; M Grace; D Boisvert
Journal:  J Neurosurg       Date:  1984-06       Impact factor: 5.115

9.  Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.

Authors:  G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

10.  Effects of nimodipine on cerebral blood flow.

Authors:  C W Haws; J K Gourley; D D Heistad
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

View more
  13 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 5.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 6.  Pharmacokinetics of calcium antagonists under development.

Authors:  D R Abernethy; J B Schwartz
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 7.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

Authors:  J H Ahmed; A C Grant; R S Rodger; G R Murray; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

9.  Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.

Authors:  J van Harten; P van Brummelen; J H Wilson; M T Lodewijks; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.